Gemfibrozil Tablet therapy should be discontinued if gallstones are found.Periodic determinations of serum lipids are necessary during treatment with gemfibrozil.
Au moins 1 % des personnes prenant ce médicament ont signalé les effets secondaires ci-après. warfarin and glimepiride), but also of CYP 2C19, CYP1A2, OATP1B1, UGTA1 and UGTA3 (see section 4.4). This risk may be increased in the elderly and in patients with hepatic or renal dysfunction. E 8 2 (Gemfibrozil 600 mg) Pill with imprint E 8 2 is White, Elliptical / Oval and has been identified as Gemfibrozil 600 mg. A population analysis of plasma bexarotene concentrations in patients with cutaneous T-cell lymphoma (CTCL) indicated that concomitant administration of gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene. Gemfibrozil also inhibits synthesis of VLDL in the liver. Il a été montré que la diminution de la concentration de cholestérol réduit le risque de maladies cardiaques, comme la crise cardiaque.La dose de gemfibrozil recommandée pour un adulte est Plusieurs facteurs peuvent entrer en ligne de compte pour déterminer la dose dont une personne a besoin : son poids, son état de santé et la prise d'autres médicaments. As the presence of food alters the bioavailability slightly gemfibrozil should be taken 30 minutes before a meal. The only dose with documented effect on morbidity is 1200mg daily. Most commonly reported adverse reactions are of gastrointestinal character and are seen in approximately 7% of the patients. The cumulative rate of cardiac end-points (cardiac death and non-fatal myocardial infarction) during a 5 year follow-up was 27.3/1,000 in the gemfibrozil group (56 subjects) and 41.4/1000 in the placebo group (84 subjects) showing a relative risk reduction of 34.0% (95% confidence interval 8.2 to 52.6, p<0.02) and an absolute risk reduction of 1.4% in the gemfibrozil group compared to placebo. Animal studies are insufficiently clear to allow conclusions to be drawn on pregnancy and foetal development (see section 5.3). Due to the lack of data, the use of gemfibrozil tablets in children is not recommended.In patients with mild to moderate renal impairment (Glomerular filtration rate 50 - 80 and 30 - < 50 ml/min/1.73 mGemfibrozil is contraindicated in hepatic impairment (see section 4.3).- Hypersensitivity to the active substance or to any of the ingredients listed in section 6.1- History of/or pre-existing gall bladder or biliary tract disease including gallstones.- Patients with previous history of photoallergy or phototoxic reaction during treatment with fibrates.- Concomitant use of repaglinide, dasabuvir, selexipag (see section 4.5), or simvastatin (see sections 4.4 and 4.5). Symptomatic supportive measures should be taken if overdose occurs.Pharmacotherapeutic group: Serum-lipid lowering agent Gemfibrozil is a non-halogenated phenoxypentanoic acid.
In a rat carcinogenicity study at dosages corresponding to 0.2 and 1.3 times the clinical exposure (based on AUC), the incidence of benign liver nodules and liver carcinomas was significantly increased in high dose males, and the incidence of liver carcinomas increased also in the low dose males, but this increase was not statistically significant. There have been reports of myositis, myopathy and markedly elevated creatine phosphokinase associated with gemfibrozil.
Elevated levels of ALAT, ASAT, alkaline phosphatase, LDH, creatine kinase (CK) and bilirubin have been reported. Gemfibrozil has also been reported to influence the pharmacokinetics of simvastatin, lovastatin, pravastatin and rosuvastatin. Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. • Fredrickson Type IIb (mixed hyperlipidaemia), Fredrickson Type III (familial dysbetalipoproteinaemia), Fredrickson Type IV (hypertriglyceridaemia) and Type V (severe hypertriglyceridaemia) with or without low HDL cholesterol Reduction of cardiovascular morbidity in males with increased non-HDL cholesterol and at high risk for a first cardiovascular event when a statin is contraindicated or not tolerated (see section 5.1). Un grand nombre de ces effets secondaires peuvent être pris en charge et quelques-uns peuvent disparaître d'eux-mêmes avec le temps.Si vous ressentez des symptômes attribuables à une dégradation musculaire comme une faiblesse généralisée, de la douleur musculaire ou un sentiment de malaise généralisé, accompagné de fièvre ou non, communiquez immédiatement avec votre médecin.Si vous observez la survenue de symptômes de troubles hépatiques comme de la fatigue, une sensation de malaise, une perte de l'appétit, de la nausée, le jaunissement de la peau ou du blanc des yeux, une urine foncée, des selles claires, une douleur abdominale, ou une enflure et une démangeaison cutanée, prenez contact avec votre médecin immédiatement.Il pourrait se produire une interaction entre le gemfibrozil et l'un des agents ci-après :Tous les contenus sont la propriété de MediResource Inc. 1996 – 2020.
Gemfibrozil caused an almost 3-fold increase in AUC of simvastatin acid possibly due to inhibition of glucoronidation via UGTA1 and UGTA3, and a 3-fold increase in pravastatin AUC which may be due to interference with transport proteins. In addition, gemfibrozil is metabolised to gemfibrozil 1-O-β-glucuronide which also inhibits CYP2C8 and OATP1B1.There have been reports of hypoglycaemic reactions after concomitant use with gemfibrozil and hypoglycaemic agents (oral agents and insulin).